Connecting parkinson's disease and drug addiction: Common players reveal unexpected disease connections and novel therapeutic approaches

Current Pharmaceutical Design

Volumn 17, Issue 5, 2011, Pages 449-461

  Gramage, Esther ^a   Herradón, Gonzalo ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Beta catenin; Drug abuse; GDNF; Midkine; Neurodegeneration; Pleiotrophin

Indexed keywords

ADDUCIN; ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLEIOTROPHIN; PROTEIN KINASE FYN; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; ASTROCYTE; ATHLETE; BLOOD BRAIN BARRIER; CELL REGENERATION; DRUG DEPENDENCE; ELECTROENCEPHALOGRAM; HUMAN; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION AND DEPHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; NERVE DEGENERATION; NERVE GROWTH FACTORS; PARKINSON DISEASE; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 79953325335     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795164103     Document Type: Article

References (178)

1. Biju G, de la Fuente-Fernandez R. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Re-lat Disord 2009; 15 Suppl 4: S38-40.
2. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson's dis-ease: features and pathophysiological mechanisms. Lancet Neurol 2009; 8: 1128-39.
3. Hauser RA. Early pharmacologic treatment in Parkinson's disease. Am J Manag Care 2010; 16 Suppl Implications: S100-7.
4. Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, et al. Treatment strategies for Parkinson's disease. Neurosci Bull 2010; 26: 66-76.
5. Chan DK, Cordato DJ, O'Rourke F. Management for motor and non-motor complications in late Parkinson's disease. Geriatrics 2008; 63: 22-7.
6. Coelho M, Ferreira J, Rosa M, Sampaio C. Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opin Pharmacother 2008; 9: 523-35.
7. Moore DJ, Dawson TM. Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep 2008; 8: 288-96.
8. Gramage E, Rossi L, Granado N, Moratalla R, Herradon G. Ge-netic inactivation of Pleiotrophin triggers amphetamine-induced cell loss in the substantia nigra and enhances amphetamine neuro-toxicity in the striatum. Neuroscience 2010; 170: 308-16.
9. Granado N, Ares-Santos S, O'Shea E, Vicario-Abejon C, Colado MI, Moratalla R. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine ad-ministration: early loss of TH in striosomes after methampheta-mine. Neurotox Res 2010; 18: 48-58.
10. Granado N, Escobedo I, O'Shea E, Colado I, Moratalla R. Early loss of dopaminergic terminals in striosomes after MDMA admini-stration to mice. Synapse 2008; 62: 80-4.
11. Herradon G, Ezquerra L. Blocking receptor protein tyrosine phos-phatase beta/zeta: a potential therapeutic strategy for Parkinson's disease. Curr Med Chem 2009; 16: 3322-9.
12. Herradon G, Ezquerra L, Gramage E, Alguacil LF. Targeting the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta signal-ing pathway to limit neurotoxicity induced by drug abuse. Mini Rev Med Chem 2009; 9: 440-7.
13. Condon J SN. Prevalence of drug use: key findings from the 2002-2003 British Crime Survey. Home Office: London 2003.
14. Parry CD, Myers B, Morojele NK, Flisher AJ, Bhana A, Donson H, et al. Trends in adolescent alcohol and other drug use: findings from three sentinel sites in South Africa (1997-2001). J Adolesc 2004; 27: 429-40.
15. Roehr B. Half a million Americans use methamphetamine every week. Bmj 2005; 331: 476.
16. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the stria-tum and substantia nigra of mice. J Neurochem 2008; 107: 1102-12.
17. Hirata H, Cadet JL. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 1997; 69: 780-90.
18. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 1996; 738: 172-5.
19. Gramage E, Putelli A, Polanco MJ, Gonzalez-Martin C, Ezquerra L, Alguacil LF, et al. The neurotrophic factor pleiotrophin modu- lates amphetamine-seeking behaviour and amphetamine-induced neurotoxic effects: evidence from pleiotrophin knockout mice. Ad-dict Biol 2010; 15: 403-12.
20. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth ac-tivity. Science 1990; 250: 1690-4.
21. Milner PG, Li YS, Hoffman RM, Kodner CM, Siegel NR, Deuel TF. A novel 17 kD heparin-binding growth factor (HBGF-8) in bo-vine uterus: purification and N-terminal amino acid sequence. Bio-chem Biophys Res Commun 1989; 165: 1096-103.
22. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. Embo J 1989; 8: 2933-41.
23. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentia-tion stages of embryonal carcinoma cells and in mid-gestation pe-riod of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-8.
24. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Pleiotro-phin: a cytokine with diverse functions and a novel signaling path-way. Arch Biochem Biophys 2002; 397: 162-71.
25. Silos-Santiago I, Yeh HJ, Gurrieri MA, Guillerman RP, Li YS, Wolf J, et al. Localization of pleiotrophin and its mRNA in sub-populations of neurons and their corresponding axonal tracts sug-gests important roles in neural-glial interactions during develop-ment and in maturity. J Neurobiol 1996; 31: 283-96.
26. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplas-tic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alter-native mechanism of receptor tyrosine kinase activation. J Biol Chem 2007; 282: 28683-90.
27. Zhang N, Zhong R, Perez-Pinera P, Herradon G, Ezquerra L, Wang ZY, et al. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Bio-chem Biophys Res Commun 2006; 343: 653-8.
28. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival,inflammation and tumorigene-sis. J Biochem 2002; 132: 359-71.
29. Yeh HJ, He YY, Xu J, Hsu CY, Deuel TF. Upregulation of plei-otrophin gene expression in developing microvasculature, macro-phages, and astrocytes after acute ischemic brain injury. J Neurosci 1998; 18: 3699-707.
30. Blondet B, Carpentier G, Lafdil F, Courty J. Pleiotrophin cellular localization in nerve regeneration after peripheral nerve injury. J Histochem Cytochem 2005; 53: 971-7.
31. Ezquerra L, Alguacil LF, Nguyen T, Deuel TF, Silos-Santiago I, Herradon G. Different pattern of pleiotrophin and midkine expres-sion in neuropathic pain: correlation between changes in pleiotro-phin gene expression and rat strain differences in neuropathic pain. Growth Factors 2008; 26: 44-8.
32. Husmann I, Soulet L, Gautron J, Martelly I, Barritault D. Growth factors in skeletal muscle regeneration. Cytokine Growth Factor Rev 1996; 7: 249-58.
33. Mi R, Chen W, Hoke A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc Natl Acad Sci U S A 2007; 104: 4664-9.
34. Hoke A. Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol 2006; 2: 448-54.
35. Jin L, Jianghai C, Juan L, Hao K. Pleiotrophin and peripheral nerve injury. Neurosurg Rev 2009; 32: 387-93.
36. Le Greves P. Pleiotrophin gene transcription in the rat nucleus accumbens is stimulated by an acute dose of amphetamine. Brain Res Bull 2005; 65: 529-32.
37. Mailleux P, Preud'homme X, Albala N, Vanderwinden JM, Van-derhaeghen JJ. delta-9-Tetrahydrocannabinol regulates gene ex-pression of the growth factor pleiotrophin in the forebrain. Neuro-sci Lett 1994; 175: 25-7.
38. Ezquerra L, Perez-Garcia C, Garrido E, Diez-Fernandez C, Deuel TF, Alguacil LF, et al. Morphine and yohimbine regulate midkine gene expression in the rat hippocampus. Eur J Pharmacol 2007; 557: 147-50.
39. Flatscher-Bader T, Wilce PA. Chronic smoking and alcoholism change expression of selective genes in the human prefrontal cor-tex. Alcohol Clin Exp Res 2006; 30: 908-15.
40. Flatscher-Bader T, Wilce PA. Impact of Alcohol Abuse on Protein Expression of Midkine and Excitatory Amino Acid Transporter 1 in the Human Prefrontal Cortex. Alcohol Clin Exp Res 2008; 32: 1849-58.
41. Herradon G, Ezquerra L, Nguyen T, Silos-Santiago I, Deuel TF. Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family. Bio- chem Biophys Res Commun 2005; 333: 714-21.
42. Marchionini DM, Lehrmann E, Chu Y, He B, Sortwell CE, Becker KG, et al. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res 2007; 1147: 77-88.
43. Ferrario JE, Rojas-Mayorquin AE, Saldana-Ortega M, Salum C, Gomes MZ, Hunot S, et al. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats. J Neurochem 2008; 107: 443-52.
44. Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, et al. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem 2004; 90: 1348-58.
45. Chen DF, Meng LJ, Du SH, Zhang HL, Li H, Zhou JH, et al.(+)-Cholesten-3-one induces differentiation of neural stem cells into dopaminergic neurons through BMP signaling. Neurosci Res 2010; 68: 176-84.
46. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without enta-capone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
47. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with par-tial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001; 16: 424-34.
48. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, et al. Chronic levodopa is not toxic for remaining do-pamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561-75.
49. Hida H, Jung CG, Wu CZ, Kim HJ, Kodama Y, Masuda T, et al. Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur J Neurosci 2003; 17: 2127-34.
50. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H. Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. Faseb J 2004; 18: 1237-9.
51. Gramage E, Alguacil LF, Herradon G. Pleiotrophin prevents co-caine-induced toxicity in vitro. Eur J Pharmacol 2008; 595: 35-8.
52. Mourlevat S, Debeir T, Ferrario JE, Delbe J, Caruelle D, Lejeune O, et al. Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: analysis of suppression-subtracted cDNA libraries and confirmation in vitro. Exp Neurol 2005; 194: 243-54.
53. Hida H, Masuda T, Sato T, Kim TS, Misumi S, Nishino H. Plei-otrophin promotes functional recovery after neural transplantation in rats. Neuroreport 2007; 18: 179-83.
54. Moses D, Drago J, Teper Y, Gantois I, Finkelstein DI, Horne MK. Fetal striatum- and ventral mesencephalon-derived expanded neu-rospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Neuroscience 2008; 154: 606-20.
55. Krasnova IN, Ladenheim B, Cadet JL. Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mito-chondria-dependent pathway. Faseb J 2005; 19: 851-3.
56. Messer CJ, Eisch AJ, Carlezon WA, Jr., Whisler K, Shen L, Wolf DH, et al. Role for GDNF in biochemical and behavioral adapta-tions to drugs of abuse. Neuron 2000; 26: 247-57.
57. Niwa M, Nitta A, Shen L, Noda Y, Nabeshima T. Involvement of glial cell line-derived neurotrophic factor in inhibitory effects of a hydrophobic dipeptide Leu-Ile on morphine-induced sensitization and rewarding effects. Behav Brain Res 2007; 179: 167-71.
58. Niwa M, Nitta A, Yamada K, Nabeshima T. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci 2007; 104: 116-21.
59. Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, et al. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine- induced rewarding effects and sensitization. Biol Psychiatry 2007; 61: 890-901.
60. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuro-science 2003; 119: 767-75.
61. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. Enhancement of locomotor activity and conditioned re-ward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999; 19: 4110-22.
62. Hall FS, Drgonova J, Goeb M, Uhl GR. Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology 2003; 28: 1485-90.
63. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 2007; 10: 1029-37.
64. Berglind WJ, See RE, Fuchs RA, Ghee SM, Whitfield TW, Jr.,Miller SW, et al. A BDNF infusion into the medial prefrontal cor-tex suppresses cocaine seeking in rats. Eur J Neurosci 2007; 26: 757-66.
65. Fumagalli F, Di Pasquale L, Caffino L, Racagni G, Riva MA. Repeated exposure to cocaine differently modulates BDNF mRNA and protein levels in rat striatum and prefrontal cortex. Eur J Neu-rosci 2007; 26: 2756-63.
66. Narita M, Miyatake M, Shibasaki M, Tsuda M, Koizumi S, Narita M, et al. Long-lasting change in brain dynamics induced by meth- amphetamine: enhancement of protein kinase C-dependent astro-cytic response and behavioral sensitization. J Neurochem 2005; 93: 1383-92.
67. Narita M, Suzuki M, Kuzumaki N, Miyatake M, Suzuki T. Implica-tion of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci 2008; 1141: 96-104.
68. Pu C, Vorhees CV. Protective effects of MK-801 on metham-phetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study. Synapse 1995; 19: 97-104.
69. Miguel-Hidalgo JJ. The role of glial cells in drug abuse. Curr Drug Abuse Rev 2009; 2: 72-82.
70. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotro-phin/heparin-binding growth-associated molecule (HB-GAM). J Biol Chem 1996; 271: 21446-52.
71. Maeda N, Noda M. Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migra-tion. J Cell Biol 1998; 142: 203-16.
72. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, et al. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic ac-tivity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci U S A 2000; 97: 2603-8.
73. Bilwes AM, den Hertog J, Hunter T, Noel JP. Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by di-merization. Nature 1996; 382: 555-9.
74. Desai DM, Sap J, Schlessinger J, Weiss A. Ligand-mediated nega-tive regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 1993; 73: 541-54.
75. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase func-tion through an inhibitory wedge. Science 1998; 279: 88-91.
76. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998; 94: 277-80.
77. Fukada M, Fujikawa A, Chow JP, Ikematsu S, Sakuma S, Noda M. Protein tyrosine phosphatase receptor type Z is inactivated by ligand-induced oligomerization. FEBS Lett 2006; 580: 4051-6.
78. Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF. Pleiotrophin regulates serine phosphorylation and the cellular dis-tribution of beta-adducin through activation of protein kinase C. Proc Natl Acad Sci U S A 2005; 102: 12407-12.
79. Pariser H, Perez-Pinera P, Ezquerra L, Herradon G, Deuel TF. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. Biochem Biophys Res Commun 2005; 335: 232-9.
80. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 2005; 332: 664-9.
81. Kawachi H, Fujikawa A, Maeda N, Noda M. Identification of GIT1/Cat-1 as a substrate molecule of protein tyrosine phosphatase zeta /beta by the yeast substrate-trapping system. Proc Natl Acad Sci U S A 2001; 98: 6593-8.
82. Tamura H, Fukada M, Fujikawa A, Noda M. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci Lett 2006; 399: 33-8.
83. Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodel- ing of the tumor microenvironment, and activation of stromal fi-broblasts. Cell Cycle 2007; 6: 2877-83.
84. Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med 2008; 86: 507-22.
85. Li YS, Deuel TF. Pleiotrophin stimulates tyrosine phosphorylation in NIH 3T3 and NB41A3 cells. Biochem Biophys Res Commun 1993; 195: 1089-95.
86. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
87. Pulford K, Morris SW, Mason DY. Anaplastic lymphoma kinase proteins and malignancy. Curr Opin Hematol 2001; 8: 231-6.
88. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002; 277: 35862-8.
89. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Plei-otrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002; 277: 14153-8.
90. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276: 16772-9.
91. Englund C, Loren CE, Grabbe C, Varshney GK, Deleuil F, Hall-berg B, et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 2003; 425: 512-6.
92. Lee HH, Norris A, Weiss JB, Frasch M. Jelly belly protein acti-vates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003; 425: 507-12.
93. Lien WH, Klezovitch O, Vasioukhin V. Cadherin-catenin proteins in vertebrate development. Curr Opin Cell Biol 2006; 18: 499-506.
94. Nelson WJ. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc Trans 2008; 36: 149-55.
95. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phos-phorylation. J Biol Chem 1999; 274: 36734-40.
96. Castelo-Branco G, Wagner J, Rodriguez FJ, Kele J, Sousa K, Rawal N, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A 2003; 100: 12747-52.
97. Kitagawa H, Ray WJ, Glantschnig H, Nantermet PV, Yu Y, Leu CT, et al. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. Mol Cell Biol 2007; 27: 7486-96.
98. Castelo-Branco G, Rawal N, Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases dif-ferentiation into dopamine neurons. J Cell Sci 2004; 117: 5731-7.
99. Liu C, Wang Y, Smallwood PM, Nathans J. An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus. J Neurosci 2008; 28: 5641-53.
100. Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, et al. Wnt1-lmx1a forms a novel autoregulatory loop and controls mid-brain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 2009; 5: 646-58.
101. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, et al. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011; 41: 508-27.
102. Ohnuki T, Nakamura A, Okuyama S, Nakamura S. Gene expres-sion profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease. Brain Res 2010; 1346: 26-42.
103. Tang M, Miyamoto Y, Huang EJ. Multiple roles of beta-catenin in controlling the neurogenic niche for midbrain dopamine neurons. Development 2009; 136: 2027-38.
104. Lynch WJ, Girgenti MJ, Breslin FJ, Newton SS, Taylor JR. Gene profiling the response to repeated cocaine self-administration in dorsal striatum: a focus on circadian genes. Brain Res 2008; 1213: 166-77.
105. Rawal N, Corti O, Sacchetti P, Ardilla-Osorio H, Sehat B, Brice A, et al. Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun 2009; 388: 473-8.
106. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev 2001; 81: 1353-92.
107. Matsuoka Y, Hughes CA, Bennett V. Adducin regulation. Defini-tion of the calmodulin-binding domain and sites of phosphorylation by protein kinases A and C. J Biol Chem 1996; 271: 25157-66.
108. Matsuoka Y, Li X, Bennett V. Adducin: structure, function and regulation. Cell Mol Life Sci 2000; 57: 884-95.
109. Asai H, Yokoyama S, Morita S, Maeda N, Miyata S. Functional difference of receptor-type protein tyrosine phosphatase zeta/beta isoforms in neurogenesis of hippocampal neurons. Neuroscience 2009; 164: 1020-30.
110. Hienola A, Pekkanen M, Raulo E, Vanttola P, Rauvala H. HB- GAM inhibits proliferation and enhances differentiation of neural stem cells. Mol Cell Neurosci 2004; 26: 75-88.
111. Hernandez-Rabaza V, Hontecillas-Prieto L, Velazquez-Sanchez C, Ferragud A, Perez-Villaba A, Arcusa A, et al. The hippocampal entate gyrus is essential for generating contextual memories of ear and drug-induced reward. Neurobiol Learn Mem 2008; 90: 553-9.
112. Meyers RA, Zavala AR, Speer CM, Neisewander JL. Dorsal hip-pocampus inhibition disrupts acquisition and expression, but not onsolidation, of cocaine conditioned place preference. Behav Neu-rosci 2006; 120: 401-12.
113. Shen F, Meredith GE, Napier TC. Amphetamine-induced place preference and conditioned motor sensitization requires activation of tyrosine kinase receptors in the hippocampus. J Neurosci 2006; 26: 11041-51.
114. Fuchs RA, Evans KA, Ledford CC, Parker MP, Case JM, Mehta RH, et al. The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats. Neuropsychopharmacology 2005; 30: 296-309.
115. Vorel SR, Liu X, Hayes RJ, Spector JA, Gardner EL. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 2001; 292: 1175-8.
116. Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Win-kler J, Gage FH, et al. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 2003; 17: 2042-6.
117. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepres- sant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
118. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running en-hances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci U S A 1999; 96: 13427-31.
119. Baker DA, Tran-Nguyen TL, Fuchs RA, Neisewander JL. Influ-ence of individual differences and chronic fluoxetine treatment on cocaine-seeking behavior in rats. Psychopharmacology (Berl) 2001; 155: 18-26.
120. Green TA, Schenk S. Dopaminergic mechanism for caffeine-produced cocaine seeking in rats. Neuropsychopharmacology 2002; 26: 422-30.
121. Kanarek RB, Marks-Kaufman R, D'Anci KE, Przypek J. Exercise attenuates oral intake of amphetamine in rats. Pharmacol Biochem Behav 1995; 51: 725-9.
122. Smith RJ, Aston-Jones G. Noradrenergic transmission in the ex-tended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 2008; 213: 43-61.
123. Stairs DJ, Klein ED, Bardo MT. Effects of environmental enrich-ment on extinction and reinstatement of amphetamine self-administration and sucrose-maintained responding. Behav Pharma-col 2006; 17: 597-604.
124. Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus 2006; 16: 233-8.
125. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-22.
126. Chambers RA, Self DW. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychophar-macology 2002; 27: 889-905.
127. Covington HE,3rd, Miczek KA. Intense cocaine self-administration after episodic social defeat stress, but not after ag-gressive behavior: dissociation from corticosterone activation. Psy-chopharmacology (Berl) 2005; 183: 331-40.
128. Erb S, Shaham Y, Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology (Berl) 1996; 128: 408-12.
129. Noonan MA, Bulin SE, Fuller DC, Eisch AJ. Reduction of adult hippocampal neurogenesis confers vulnerability in an animal model of cocaine addiction. J Neurosci 2010; 30: 304-15.
130. Lavaur J, Mineur YS, Picciotto MR. The membrane cytoskeletal protein adducin is phosphorylated by protein kinase C in D1 neu-rons of the nucleus accumbens and dorsal striatum following co-caine administration. J Neurochem 2009; 111: 1129-37.
131. Ditlevsen DK, Berezin V, Bock E. Signalling pathways underlying neural cell adhesion molecule-mediated survival of dopaminergic neurons. Eur J Neurosci 2007; 25: 1678-84.
132. Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibi-tors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 2010; 40: 211-6.
133. Wang J, Carnicella S, Phamluong K, Jeanblanc J, Ronesi JA, Chaudhri N, et al. Ethanol induces long-term facilitation of NR2B-NMDA receptor activity in the dorsal striatum: implications for al-cohol drinking behavior. J Neurosci 2007; 27: 3593-602.
134. Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics-an update. Eur J Pharmacol 2008; 579: 1-12.
135. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
136. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Park-inson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102: 216-22.
137. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005; 11: 703-4.
138. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-66.
139. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neu-rotrophic factor therapy for Parkinson's disease. Prog Brain Res 2010; 184: 237-64.
140. Yasuda T, Mochizuki H. Use of growth factors for the treatment of Parkinson's disease. Expert Rev Neurother 2010; 10: 915-24.
141. Vastag B. Biotechnology: Crossing the barrier. Nature 2010; 466: 916-8.
142. Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. Brain Res 2011; 1369: 203-7.
143. Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein. Brain Res 2010; 1360: 193-7.
144. Fu A, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Intra-venous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res 2010; 1352: 208-13.
145. Boado RJ, Lu JZ, Hui EK, Pardridge WM. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng 2010; 105: 627-35.
146. Christman KL, Fang Q, Kim AJ, Sievers RE, Fok HH, Candia AF, et al. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem Biophys Res Commun 2005; 332: 1146-52.
147. Ezquerra L, Herradon G, Nguyen T, Vogt TF, Bronson R, Silos-Santiago I, et al. Pleiotrophin is a major regulator of the catechola-mine biosynthesis pathway in mouse aorta. Biochem Biophys Res Commun 2004; 323: 512-7.
148. Herradon G, Ezquerra L, Nguyen T, Vogt TF, Bronson R, Silos-Santiago I, et al. Pleiotrophin is an important regulator of the renin-angiotensin system in mouse aorta. Biochem Biophys Res Com-mun 2004; 324: 1041-7.
149. Harroch S, Palmeri M, Rosenbluth J, Custer A, Okigaki M, Shrager P, et al. No obvious abnormality in mice deficient in receptor pro-tein tyrosine phosphatase beta. Mol Cell Biol 2000; 20: 7706-15.
150. Niisato K, Fujikawa A, Komai S, Shintani T, Watanabe E, Sakagu-chi G, et al. Age-dependent enhancement of hippocampal long-term potentiation and impairment of spatial learning through the Rho-associated kinase pathway in protein tyrosine phosphatase re-ceptor type Z-deficient mice. J Neurosci 2005; 25: 1081-8.
151. Harroch S, Furtado GC, Brueck W, Rosenbluth J, Lafaille J, Chao M, et al. A critical role for the protein tyrosine phosphatase recep-tor type Z in functional recovery from demyelinating lesions. Nat Genet 2002; 32: 411-4.
152. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 410-25.
153. Matsui T, Ichihara-Tanaka K, Lan C, Muramatsu H, Kondou T, Hirose C, et al. Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds. Int Arch Med 2010; 3: 12.
154. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204: 127-43.
155. Hendriks WJ, Elson A, Harroch S, Stoker AW. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. Febs J 2008; 275: 816-30.
156. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006; 6: 307-20.
157. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
158. Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsdui-jnen R, Wesseling P, Hendriks WJ. Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 2010; 119: 157-75.
159. Tabernero L, Aricescu AR, Jones EY, Szedlacsek SE. Protein tyrosine phosphatases: structure-function relationships. Febs J 2008; 275: 867-82.
160. Ventura JJ, Nebreda AR. Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 2006; 8: 153-60.
161. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 2009; 16: 706-33.
162. Rye CS, Baell JB. Phosphate isosteres in medicinal chemistry. Curr Med Chem 2005; 12: 3127-41.
163. Evdokimov AG, Pokross M, Walter R, Mekel M, Cox B, Li C, et al. Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery. Acta Crystal-logr D Biol Crystallogr 2006; 62: 1435-45.
164. Grucza RA, Bradshaw JM, Futterer K, Waksman G. SH2 domains: from structure to energetics, a dual approach to the study of struc-ture-function relationships. Med Res Rev 1999; 19: 273-93.
165. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation seg-ment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000; 6: 1401-12.
166. Andersen HS, Iversen LF, Jeppesen CB, Branner S, Norris K, Rasmussen HB, et al. 2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J Biol Chem 2000; 275: 7101-8.
167. Burke TR, Jr., Zhang ZY. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 1998; 47: 225-41.
168. Iversen LF, Andersen HS, Branner S, Mortensen SB, Peters GH, Norris K, et al. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of pro-tein-tyrosine phosphatase 1B. J Biol Chem 2000; 275: 10300-7.
169. Tam S, Saiah E. Recent advances in the discovery and development of PTP-1B inhibitors. Drugs of the future 2008; 33: 175-85.
170. Pulido R, Hooft van Huijsduijnen R. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. Febs J 2008; 275: 848-66.
171. Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, et al. Synthe-sis and biological evaluation of rhodanine derivatives as PRL-3 in-hibitors. Bioorg Med Chem Lett 2006; 16: 2996-9.
172. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, Yi T. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 2002; 1: 1255-64.
173. Hoffman BT, Nelson MR, Burdick K, Baxter SM. Protein tyrosine phosphatases: strategies for distinguishing proteins in a family con-taining multiple drug targets and anti-targets. Curr Pharm Des 2004; 10: 1161-81.
174. Huang P, Ramphal J, Wei J, Liang C, Jallal B, McMahon G, et al. Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2003; 11: 1835-49.
175. Bouyain S, Watkins DJ. The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules. Proc Natl Acad Sci U S A 2010; 107: 2443-8.
176. Croasdell G. American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2. IDrugs 2010; 13: 598-600.
177. Xie Y, Massa SM, Ensslen-Craig SE, Major DL, Yang T, Tisi MA, et al. Protein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function. J Biol Chem 2006; 281: 16482-92.
178. Shintani T, Noda M. Protein tyrosine phosphatase receptor type Z dephosphorylates TrkA receptors and attenuates NGF-dependent neurite outgrowth of PC12 cells. J Biochem 2008; 144: 259-66.